The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis

References

• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)DaviesCGodwinJRelevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsLancet2011378979377178421802721
   PubMed Web of Science ®Google Scholar
• FabianCTilzerLSternsonLComparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancerBiopharm Drug Dispos1981243813907317574
   PubMed Web of Science ®Google Scholar
• KleinDJThornCFDestaZFlockhartDAAltmanRBKleinTEPharmGKB summary: tamoxifen pathway, pharmacokineticsPharmacogenet Genomics2013231164364723962908
   PubMed Web of Science ®Google Scholar
• KiyotaniKMushirodaTImamuraCKSignificant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patientsJ Clin Oncol20102881287129320124171
   PubMed Web of Science ®Google Scholar
• SchrothWGoetzMPHamannUAssociation between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenJAMA2009302131429143619809024
   PubMed Web of Science ®Google Scholar
• MargolinSLindhJDThorenLCYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patientsPharmacogenomics201314661362223570465
   PubMedGoogle Scholar
• TehLKMohamedNISallehMZThe risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1AAPS J2012141525922183189
   PubMed Web of Science ®Google Scholar
• GoetzMPSumanVJHoskinTLCYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8Clin Cancer Res201319250050723213055
   PubMed Web of Science ®Google Scholar
• BonanniBMacisDMaisonneuvePPolymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen TrialJ Clin Oncol200624223708370916877740
   PubMed Web of Science ®Google Scholar
• GoetzMPSchaidDJWickerhamDLEvaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trialsClin Cancer Res201117216944695121880792
   PubMed Web of Science ®Google Scholar
• RaeJMDrurySHayesDFCYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJ Natl Cancer Inst2012104645246022395643
   PubMed Web of Science ®Google Scholar
• ReganMMLeyland-JonesBBouzykMBreast International Group (BIG) 1–98 Collaborative GroupCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trialJ Natl Cancer Inst2012104644145122395644
   PubMed Web of Science ®Google Scholar
• SestakIKealyRNikoloffMRelationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trialBr J Cancer2012107223023322735900
   PubMed Web of Science ®Google Scholar
• KiyotaniKMushirodaTZembutsuHNakamuraYImportant and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studiesJ Hum Genet201358632733323657426
   PubMedGoogle Scholar
• LienEASoilandHLundgrenSSerum concentrations of tamoxifen and its metabolites increase with age during steady-state treatmentBreast Cancer Res Treat2013141224324823996142
   PubMed Web of Science ®Google Scholar
• ZangerUMRaimundoSEichelbaumMCytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistryNaunyn Schmiedebergs Arch Pharmacol20043691233714618296
   PubMed Web of Science ®Google Scholar
• JungJALimHSAssociation between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysisPharmacogenomics2014151496024329190
   PubMed Web of Science ®Google Scholar
• SakuyamaKSasakiTUjiieSFunctional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57)Drug Metab Dispos200836122460246718784265
   PubMed Web of Science ®Google Scholar
• GaedigkAGotschallRRForbesNSSimonSDKearnsGLLeederJSOptimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency dataPharmacogenetics19999666968210634130
   PubMedGoogle Scholar
• JohanssonIOscarsonMYueQYBertilssonLSjöqvistFIngelman-SundbergMGenetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylationMol Pharmacol19944634524597935325
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analyzesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• BohningDMeta-analysis: a unifying meta-likelihood approach framing unobserved heterogeneity, study covariates, publication bias, and study qualityMethods Inf Med200544112713515778804
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• HarbordRMEggerMSterneJAA modified test for small-study effects in meta-analyzes of controlled trials with binary endpointsStat Med200625203443345716345038
   PubMed Web of Science ®Google Scholar
• ChamnanphonMPechatananKSirachainanEAssociation of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifenPharmgenomics Pers Med20136374823776391
   PubMedGoogle Scholar
• KiyotaniKMushirodaTSasaMImpact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapyCancer Sci200899599599918294285
   PubMed Web of Science ®Google Scholar
• LeiLWangXWuXDAssociation of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese populationAm J Transl Res2016883585359227648149
   PubMed Web of Science ®Google Scholar
• SensornISukasemCSirachainanEABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifenOnco Targets Ther201692121212927110128
   PubMed Web of Science ®Google Scholar
• SirachainanEJaruhathaiSTrachuNCYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patientsPharmgenomics Pers Med2012514915323226070
   PubMedGoogle Scholar
• SukasemCSirachainanEChamnanphonMImpact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in ThailandAsian Pac J Cancer Prev20121394549455323167378
   PubMedGoogle Scholar
• TianCYangYLiHCorrelation between CYP2D6* 10 gene polymorphism and prognosis of breast cancer patients treated with tamoxifenChin J Breast Dis201376406411
   Google Scholar
• WangYYChengGHPuZCPolymorphisms of CYP2D6*10 and CYP2C19*2 and its effect on breast cancer patients with tamoxifen treatmentChin Clin Pharmacol Ther2015205552556
   Google Scholar
• WeiYXuZAssociation between CYP2D6* 10 genotype and survival of breast cancer patients receiving tamoxifen treatmentAnhui Med Pharm J2014185951954
   Google Scholar
• XiaoGLiDLiuLXClinical snalyisi of CYP2D6 gene polymorphism and Tamoxifen efficacy in post-menopause breast cancer patientsJ Ningxia Med Univ2014363315318
   Google Scholar
• XuYSunYYaoLAssociation between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatmentAnn Oncol20081981423142918407954
   PubMed Web of Science ®Google Scholar
• YuYYouWLiangDEfects of CYP2 D6 gene polymorphism on prognosis of ER-positive breast cancer patients treated with tamoxifen therapyShandong Med201656421720
   Google Scholar
• ZengYHuangKHuangWThe effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancerPak J Pharm Sci2017303(Special)1095109828671087
   PubMedGoogle Scholar
• ZhangXPuZGeJShenJYuanXXieHAssociation of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapyMed Sci Monit20152156356925701109
   PubMed Web of Science ®Google Scholar
• NovilloARomero-LorcaAGaibarMRubioMFernández-SantanderATamoxifen metabolism in breast cancer treatment: taking the focus off the CYP2D6 genePharmacogenomics J201717210911127698402
   PubMedGoogle Scholar
• AreepiumNPanomvanaDRungwanonchaiPSathapornSVoravudNEffects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patientsBreast Cancer (Dove Med Press)20135737824648760
   PubMedGoogle Scholar
• Del ReMRofiECitiVShould CYP2D6 be genotyped when treating with tamoxifen?Pharmacogenomics201718875575628593824
   PubMedGoogle Scholar
• ProvinceMAGoetzMPBrauchHInternational Tamoxifen Pharmacogenomics ConsortiumCYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populationsClin Pharmacol Ther201495221622724060820
   PubMed Web of Science ®Google Scholar
• JohanssonHGandiniSSerranoDA pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifenBreast Cancer Res Treat201615919710827484880
   PubMedGoogle Scholar
• LimHSJu LeeHSeok LeeKSook LeeEJangIJRoJClinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancerJ Clin Oncol200725253837384517761971
   PubMed Web of Science ®Google Scholar
• OkishiroMTaguchiTJin KimSShimazuKTamakiYNoguchiSGenetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifenCancer2009115595296119156902
   PubMedGoogle Scholar
• AbreuMHGomesMMenezesFCYP2D6*4 polymorphism: a new marker of response to hormonotherapy in male breast cancer?Breast201524448148625963137
   PubMedGoogle Scholar
• DezentjeVOvan SchaikRHVletter-BogaartzJMCYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trialBreast Cancer Res Treat2013140236337323842856
   PubMed Web of Science ®Google Scholar